The European Commission is taking steps to ensure that ongoing challenges posed by the implementation of the In Vitro Diagnostic Regulation (IVDR) does not cause unintentional delays to drug clinical trials that are to be run in combination with IVD studies.
Concerns on this front were highlighted in a recent survey by the European industry federation for research-based drug companies, EFPIA. The survey showed that between 82 and 160 drug trials...